SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million Versus Quarter Ended June 30, 2025

Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million

GALT

Related stories